|
1
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
LaFleur MW, Muroyama Y, Drake CG and
Sharpe AH: Inhibitors of the PD-1 pathway in tumor therapy. J
Immunol. 200:375–383. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang T, Xie J, Arai S, Wang L, Shi X, Shi
N, Ma F, Chen S, Huang L, Yang L, et al: The efficacy and safety of
anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory
cancers: A meta-analysis. Oncotarget. 7:73068–73079. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hida T, Nishio M, Nogami N, Ohe Y,
Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H,
et al: Efficacy and safety of nivolumab in Japanese patients with
advanced or recurrent squamous non-small cell lung cancer. Cancer
Sci. 108:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishio M, Hida T, Atagi S, Sakai H,
Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo
M, et al: Multicentre phase II study of nivolumab in Japanese
patients with advanced or recurrent non-squamous non-small cell
lung cancer. ESMO Open. 1:e0001082017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brodowicz T, O'Byrne K and Manegold C:
Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsuya A, Kurata T, Tamura K and Fukuoka M:
Skeletal metastases in non-small cell lung cancer: A retrospective
study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hamaoka T, Costelloe CM, Madewell JE, Liu
P, Berry DA, Islam R, Theriault RL, Hortobagyi GN and Ueno NT:
Tumour response interpretation with new tumour response criteria vs
the World Health Organisation criteria in patients with bone-only
metastatic breast cancer. Br J Cancer. 102:651–657. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Costelloe CM, Chuang HH, Madewell JE and
Ueno NT: Cancer response criteria and bone metastases: RECIST 1.1,
MDA and PERCIST. J Cancer. 1:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashi N, Costelloe CM, Hamaoka T, Wei C,
Niikura N, Theriault RL, Hortobagyi GN, Madewell JE and Ueno NT: A
prospective study of bone tumor response assessment in metastatic
breast cancer. Clin Breast Cancer. 13:24–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamashita Y, Aoki T, Hanagiri T, Yoshii C,
Mukae H, Uramoto H and Korogi Y: Osteosclerotic lesions in patients
treated with gefitinib for lung adenocarcinomas: A sign of
favorable therapeutic response. Skeletal Radiol. 41:409–414. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rong D, Mao Y, Yang Q, Xu S, Zhao Q and
Zhang R: Early osteosclerotic changes predict chemotherapy response
in non-small-cell lung cancer patients with bone metastases. Eur
Radiol. 28:4362–4369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang CY, Simeone FJ, Torriani M and
Bredella MA: Quantitative contrast-enhanced CT attenuation
evaluation of osseous metastases following chemotherapy. Skeletal
Radiol. 46:1385–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amir E, Whyne C, Freedman OC, Fralick M,
Kumar R, Hardisty M and Clemons M: Radiological changes following
second-line zoledronic acid treatment in breast cancer patients
with bone metastases. Clin Exp Metastasis. 26:479–484. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vassiliou V, Kalogeropoulou C,
Christopoulos C, Solomou E, Leotsinides M and Kardamakis D:
Combination ibandronate and radiotherapy for the treatment of bone
metastases: Clinical evaluation and radiologic assessment. Int J
Radiat Oncol Biol Phys. 67:264–272. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Quattrocchi CC, Piciucchi S, Sammarra M,
Santini D, Vincenzi B, Tonini G, Grasso RF and Zobel BB: Bone
metastases in breast cancer: Higher prevalence of osteosclerotic
lesions. Radiol Med. 112:1049–1059. 2007.(In Italian). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakata E, Sugihara S, Kataoka M, Yamashita
N, Furumatsu T, Takigawa T, Tetsunaga T and Ozaki T: Early response
assessment of re-ossification after palliative conventional
radiotherapy for vertebral bone metastases. J Orthop Sci.
24:332–336. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gettinger S, Horn L, Jackman D, Spigel D,
Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC,
et al: Five-year follow-up of nivolumab in previously treated
advanced non-small-cell lung cancer: Results from the CA209-003
study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nadal E, Massuti B, Dómine M,
García-Campelo R, Cobo M and Felip E: Immunotherapy with checkpoint
inhibitors in non-small cell lung cancer: Insights from long-term
survivors. Cancer Immunol Immunother. 68:341–352. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blons H, Garinet S, Laurent-Puig P and
Oudart JB: Molecular markers and prediction of response to
immunotherapy in non-small cell lung cancer, an update. J Thorac
Dis. 11 (Suppl 1):S25–S36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Prelaj A, Tay R, Ferrara R, Chaput N,
Besse B and Califano R: Predictive biomarkers of response for
immune checkpoint inhibitors in non-small-cell lung cancer. Eur J
Cancer. 106:144–159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoneda T and Hiraga T: Crosstalk between
cancer cells and bone microenvironment in bone metastasis. Biochem
Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sterling JA, Edwards JR, Martin TJ and
Mundy GR: Advances in the biology of bone metastasis: How the
skeleton affects tumor behavior. Bone. 48:6–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
